-+ 0.00%
-+ 0.00%
-+ 0.00%

VolitionRx highlights $5 million feline paper milestone in corporate deck

PUBT·09/10/2026 11:17:05
Listen to the news
VolitionRx highlights $5 million feline paper milestone in corporate deck
  • VolitionRx outlined an asset-light strategy focused on licensing Nu.Q technology across cancer, sepsis, and veterinary diagnostics.
  • Reported USD 23 million in licensing and USD 1.4 million revenue in H1 2026.
  • Flagged a potential USD 5 million contractual milestone tied to publication of a feline lymphoma manuscript.
  • Nu.Q Vet canine cancer screening launched on the IDS i10 automated analyzer via Fujifilm Vet Systems.
  • Government-backed DETECSEPS sepsis program in France, financed at about USD 7.3 million, targeted for Q3 2026 launch.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief on September 10, 2026, and is solely responsible for the information contained therein.